
## **Supplemental Material**

#### **Supplemental References**


Chu X, Erdman R, Susek M, Gerst H, Derr K, Al-Agha M, Wood GC, Hartman C, Yeager S, Blosky MA, Krum W, Stewart WF, Carey D, Benotti P, Still CD, Gerhard GS (2008) Association of morbid obesity with FTO and INSIG2 allelic variants. Arch Surg (United States) 143:235-40

Gerhard GS, Langer RD, Carey DJ, Stewart WF (2010) Electronic medical records in genomic medicine practice and research. In: Genomic and personalized medicine (Ginsburg, GS and Willard HF, ed), pp142-151.Academic Press/Elsevier.


# **Supplemental Figures & Tables**



**Supplemental Figure 1**. Weight loss in RYGB patients  $24 \pm 3$  months after surgery. Number of patients in each group is indicated above the bars.



**Supplemental Figure 2.** Weight loss in patients undergoing RYGB stratified by MC4R genotype expressed as percent excess body weight loss (EBWL). Excess body weight is defined based an idealized BMI of 25 kg/m<sup>2</sup>.



Supplemental Figure 3. Post-RYGB weight loss stratified by diabetic status for *Reference* and *I251L* allele carriers. Weight loss reported as %kg at surgery is shown for the two groups based on pre-surgery diabetic status.

# Supplemental Table 1.

Study cohorts (Means  $\pm$  SEM).

	Obese (RYGB)	Lean (Control)
Number of subjects	1433	451
Average BMI	46.6 <u>+</u> 0.001	23.1 <u>+</u> 0.001
Average age	45.8 + 0.002	49.5 + 0.02
% Female	79.9	68.5

## Supplemental Table 2.

Genotype	Obese	Control	Odd Ratios (95% CI)
V103I	36/1433 (2.5%)	18/451 (4.0%)	0.62 (0.35-1.10)
I251L	26/1433 (1.8%)	6/451 (1.3%)	1.37 (0.56-3.35)

One of the subjects in the obese group was homozygous for V103I allele. Two-sided p values for allele frequency between the obese and control groups for V103I and I251L are 0.1 and 0.7, respectively (Fisher's exact test).

## **Supplemental Table 3.**

Obese cohort stratified by genotype (Means  $\pm$  SEM).

	Reference	I251L	V103I
Subjects (n)	1353	26	36
Female (n)	1077	23	28
Age (years)	46 <u>+</u> 0.3	47 <u>+</u> 2	46 <u>+</u> 2
BMI (kg/m <sup>2</sup> )	47 <u>+</u> 0.2	47 <u>+</u> 2	48 <u>+</u> 2
Ethnicity (n)			
White/Caucasian	1283	26	32
Black/African-American	27		1
Hispanics	12		
Other	1		
Data not collected	33		3

#### Supplement Table 4.

Diabetic status of study cohort

	Reference	I251L	
Total (n)	1269	25	
Dysglycemics <sup>§</sup> , n (%)	776 (62)	14 (56)	

<sup>§</sup> Dysglycemics (Diabetics and pre-diabetics) were identified as those with  $Hb_{A1c} \ge 6.0$  or taking therapy ( biguanides, insulin, insulin-sensitizing agents, sulfonylureas) at time of surgery.

## **Supplemental Table 5.**

		Reference	I251L	P value <sup>¥</sup>
ALT (units/L)	Total	$31 \pm 0.7$ (810)	23 ± 2 (19) **	0.001
	Normoglycemic §	$29 \pm 0.7$ (500)	23 ± 3 (12)	0.2
	Dysglycemic <sup>§</sup>	33 ± 1 (310) ##	23 ± 1 (7) ***	0.0001
AST (units/L)	Total	$26 \pm 1$ (808)	22 ± 1 (19) ***	0.0005
	Normoglycemic	$25 \pm 1$ (498)	$21 \pm 2$ (12)	0.05
	Dysglycemic	29 ± 1 (310) ##	22 ± 1 (7) ***	0.0002
Alkaline Phosphatase	Total	79 ± 1 (809)	84 ± 5 (19)	0.3
(units/L)	Normoglycemic	78 ± 1 (499)	85 ± 7 (12)	0.2
	Dysglycemic	80 ± 2 (310)	$82 \pm 7$ (7)	0.8
Triglyc. (mg/dL)	Total	168 ± 3 (811)	148 ± 12 (19)	0.2
	Normoglycemic	153 ± 4 (499)	138 <u>+</u> 12 (12)	0.2
	Dysglycemic	191 ± 7 (312) ###	167 <u>+</u> 29 (7)	0.6
Chol. (mg/dL)	Total	190 ± 1 (813)	202 ± 7 (19)	0.2
	Normoglycemic	190 ± 2 (499)	201 ± 9 (12)	0.3
	Dysglycemic	191 ± 2 (314)	205 ± 12 (7)	0.3
LDL (mg/dL)	Total	$110 \pm 1$ (802)	$123 \pm 8 (19)$	0.07
	Normoglycemic	112 ± 1 (495)	$123 \pm 10$ (12)	0.2
	Dysglycemic	$108 \pm 2$ (307) <sup>#</sup>	124 ± 15 (7)	0.2
HDL (mg/dL)	Total	47 ± 0.4 (811)	49 ± 3 (19)	0.5
	Normoglycemic	$48 \pm 0.5$ (499)	50 ± 4 (12)	0.4
	Dysglycemic	$47 \pm 0.7$ (312)	48 ± 5 (7)	0.7
Chol/HDL ratio	Total	4.3 ± 0.08 (811)	$4.4 \pm 0.3$ (19)	0.8
	Normoglycemic	$4.3 \pm 0.12$ (499)	$4.2 \pm 0.3$ (12)	0.9
	Dysglycemic	$4.3 \pm 0.07$ (312)	$4.5 \pm 0.4$ (7)	0.6

Additional Clinical Parameters at Time of Surgery: Mean  $\pm$  SEM (n)

<sup>§</sup> Dysglycemics (diabetics and pre-diabetics) were identified as described in Supplemental Table 4 above.

Subjects taking cholesterol absorption medicines (statins) were excluded from these calculations.

<sup>¥</sup> p values from unpaired t -test between genotypes using Welch's correction for unequal variances whenever necessary, \*\*\* p<0.001 vs. corresponding *Reference* genotype.

Unpaired t-test with Welch's corrections for unequal variances whenever necessary was used to compare within genotype between dysglycemic and normoglycemic groups, #p < 0.05, ### p < 0.001 vs. non-diabetic group of the same genotype.